Newsroom | 9408 results

PALO ALTO, Calif.--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced that on April 21, 2026, the Compensation Committee of Guardant’s Board of Directors approved the granting of restricted stock units (“RSUs”) representing 143,898 shares of its common stock to 267 new non-executive employees with a grant date of May 11, 2026 under the Guardant Health, Inc. 2023 Employment Inducement Incentive Award Plan (the “Inducement Plan”). The RSUs w...

SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, today announced that the New England Journal of Medicine has published the full results of its TETON-1 study, as well as combined analyses of its TETON-1 and TETON-2 studies, evaluating the use of nebulized Tyvaso for the treatment of IPF. The publication is available here. A summary of the publication was also presented today during a symposium at th...

BOSTON--(BUSINESS WIRE)--Amplitude Vascular Systems (AVS), a medical device company recently acquired by Stryker and focused on treating severely calcified arterial disease, today announced the enrollment of the first patient in its first-in-human (FIH) study for Pulsatile Intravascular Lithotripsy (PIVL) therapy in a coronary indication. The POWER CAD I study will evaluate the feasibility of the Pulse IVL™ System for the treatment of patients with moderate to severely calcified coronary arteri...

WHIPPANY, N.J.--(BUSINESS WIRE)--U.S. FDA Grants Priority Review to sNDA for HYRNUO® (sevabertinib) Under Investigation as a First-Line Treatment of HER2-Mutated NSCLC...

ALAMEDA, Calif.--(BUSINESS WIRE)--Scribe Therapeutics reports preclinical data at ASGCT 2026 demonstrating enhanced potency and specificity of engineered CRISPR technologies...

CHARLOTTE, N.C.--(BUSINESS WIRE)--For a second year in a row, Bojangles and The Bojangles Foundation partnered with NFL legend Greg Olsen’s The HEARTest Yard Foundation for a heartwarming “Bojangles Gives from the Heart” initiative. This partnership raised $659,542.54 through sales of the iconic Heart-Shaped Bo-Berry Biscuits® and a guest round-up campaign, exceeding its fundraising goal to support pediatric heart care, family support programs and congenital heart defect research. “This partner...

HERZLIYA, Israel--(BUSINESS WIRE)--Endospan, a pioneer in endovascular solutions for complex aortic pathologies, today announced that Artivion, Inc. (NYSE: AORT) has closed the transaction to acquire the company. This strategic milestone follows the April 2026 U.S. Food and Drug Administration (FDA) PMA approval of the NEXUS® Aortic Arch System, the first off-the-shelf endovascular solution designed to treat aortic arch disease, including chronic aortic dissections, in patients at high risk for...

SAN DIEGO--(BUSINESS WIRE)--Gossamer Bio, Inc. (Nasdaq: GOSS), a clinical-stage biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD), today announced its financial results for the first quarter ended March 31, 2026, and provided a business update. Gossamer Bio and the Chiesi Group are jointly developing seralutinib under a...

SANTA CLARA, Calif.--(BUSINESS WIRE)--VahatiCor, Inc., a medtech company developing interventional therapies for Coronary Microvascular Dysfunction (CMD), announced today the appointment of Harry D. Rowland, Ph.D., as Chief Executive Officer. Rowland previously served as Chief Executive Officer and President of Endotronix, where he led the development and commercialization of the Cordella™ Pulmonary Artery Sensor and Heart Failure System. Under his leadership, Endotronix raised over $150 millio...

PARIS & DALLAS--(BUSINESS WIRE)--Tulyp Medical, a Paris-based medical device company developing an intelligent pressure-driven perfusion system, today announced the appointment of Steve Motes as Chief Executive Officer. The appointment follows positive results from the company’s first-in-human study. Steve joins Tulyp with more than 30 years of experience in the medical device industry, primarily focused on cardiovascular technologies. He has held leadership roles at Draeger, Medtronic (formerl...